Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Research Abstract |
Bone marrow-derived fibrocytes reportedly play important roles in the pathogenesis of idiopathic pulmonary fibrosis. Pirfenidone (PFD) is an anti-fibrotic agent; however, its effects on fibrocytes have not been investigated. The aim of this study was to investigate whether PFD inhibits fibrocyte pool size in the lungs of bleomycin (BLM)-treated mice. To achieve this, C57BL/6 mice were treated with BLM and PFD was administered. Fibrocyte pool size in BLM-treated mice lungs was attenuated by PFD. This was also observed in a therapeutic setting. Increased chemokine (CC motif) ligand-2 (CCL2) and CCL12 production in BLM-treated mouse lungs was significantly attenuated by PFD. Fibrocyte migration toward CCL2 and chemokine (CC motif) receptor-2 expression on fibrocytes were significantly inhibited by PFD in vitro. Fibrocyte inhibition is considered a mechanism of anti-fibrotic action of PFD.
|